Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lamotrigine Monotherapy in Pediatric Bipolar Disorder

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2007 by University of Illinois at Chicago.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
University of Illinois at Chicago
ClinicalTrials.gov Identifier:
NCT00176228
First received: September 13, 2005
Last updated: April 18, 2007
Last verified: April 2007
  Purpose

There are two purposes for this project. Study 1 is intended to study the safety and efficacy of Lamotrigine in stabilizing the mood in all phases of pediatric bipolar disorder (Phases: mixed, manic, hypomanic, or depressed episodes) in 8-17 year old children. These children and adolescents must be treatment resistant (who failed on two adequate trials of mood stabilizing medications) to qualify for this study. Study 2 is aimed at examining brain activity and/or dysfunction before lamotrigine treatment, and to look for any alteration after lamotrigine treatment. Brain systems associated with attention and emotional processing will targeted.


Condition Intervention Phase
Bipolar Disorder
Drug: Lamotrigine
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Trial of Lamotrigine Monotherapy in Pediatric Bipolar Disorder

Resource links provided by NLM:


Further study details as provided by University of Illinois at Chicago:

Primary Outcome Measures:
  • Young Mania Rating Scale (YMRS),
  • Bipolar Clinical Global Impression Scale (BP-CGI),
  • Overt Aggression Scale (OAS),
  • Child Depression Rating Scale-Revised (CDRS-R),
  • Brief Psychiatric Rating Scale in Children (BPRS-C),
  • Child Bipolar Rating Scale- Parent version (subscales: Child Mania Rating Scale,
  • Child Bipolar Depression Rating Scale,
  • Child Bipolar Cycling Rating Scale) and Teacher version (subscales: Child Mania Rating Scale,
  • Child Bipolar Depression Rating Scale)(CBRS-P/T),
  • Abnormal Involuntary Movements Scale (AIMS),
  • Pediatric Side Effects Rating Scale (P-SERS),
  • CAFAS (Child and Adolescent Functional Assessment Scale)

Estimated Enrollment: 45
Study Start Date: February 2004
Estimated Study Completion Date: January 2008
Detailed Description:

Procedure Study 1 This study is planned to be conducted over 18 months, with an average recruitment of 2 subjects per month. Each subject is involved in the study for 18 to 26 weeks. The range of time is necessary to account for factors such as the child’s age, sex, weight, reactions to the medications and side effects. Based on these factors, the time it takes to titrate the medication dose to the optimal amount will vary. Maintaining this flexibility in the protocol is part of good clinical practice where medication is involved. Only children whose medication is not currently improving their symptoms will be recruited. Therefore no children who have been stabilized on a drug will be taken off of it. The initial 2-week screening period includes a diagnostic interview and collection of demographic information. Previous medication will be tapered slowly over this 2-week period. It is an open trial where subjects are aware of the type of medication and the strength (For example, one pill=25 mg strength) of the pill. Research assessment of mood symptoms and side effects will be carried out 5 times over the course of the active trial period. Blood will be collected 3 times: once the subject is washed-out (baseline), once optimal medication dose has been reached, and finally at the end of the 6-week period on full dose.

The dose of Lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg. Increasing the medication to final dose will take approximately 10-18 weeks (depending on age, weight and side-effect profile of each subject on a case-by-case basis) and the response on full and tolerable dose is further monitored for response over 6 weeks. Therefore, this is a 18-26 week trial (2 weeks=screening and wash out; 10-18 weeks=dosing; 6 weeks=acute trial period on full dose).

Study 2 involves adolescent subjects (>10years of age) recruited from the Study 1 sample. This part of the study is a fMRI treatment study to examine how the brain functions before and after receiving lamotrigine medication for bipolar disorder. The goal of study 2 is to understand how and where lamotrigine works in the brain. In order to do this, we will view brain images in a fMRI scanner pre- and post-treatment. This will be done once before subjects begin taking lamotrigine (subjects who require a “wash-out” period, described in study 1, this will occur after the “wash-out.”) The second scan will take place after the medication trial (after the 6-week active treatment period). While in the scanner, subjects will complete tasks related to thinking and emotion. Subjects will be shown pictures of faces with varying expressions including happy, neutral and angry and will be asked to identify the emotions of the faces, remember and identify previously seen faces, and determine the age group of various faces (i.e., above or below 30 years). Subjects will also complete tasks that involve processing words that express different emotions (e.g., happy, angry), and respond to different “go” and “no-go” images that flash on a screen. Brain activity will be recorded during these tasks. Each task will take around 5 minutes. Before the actual fMRI scan, subjects practice lying in a simulator, a machine that looks and sounds like a scanner.

  Eligibility

Ages Eligible for Study:   10 Years to 20 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ages 10-20
  • Must be able to swallow tablets
  • Must be diagnosed with bipolar disorder

Exclusion Criteria:

  • Children with general medical condition such as head injury, epilepsy, endocrine disorders
  • Those who are on mood altering medications such as steroids, and those diagnosed with mental retardation are excluded to avoid confounding and contributing factors to mood swings.
  • If we discover during the interview that the parent and/or child does not understand the consent/assent procedures, we will exclude them.
  • Girls who are pregnant or plan to become pregnant during the study period will also be excluded from the research. There have been no concerns raised in the literature about the need for birth control practices in males treated with lamotrigine. As such, there are no provisions to exclude males from the research who do not practice birth control.

We expect only a small number of children to be excluded from the study due to exclusionary criteria. Selection of the subjects is not based on sex, race, or ethnic group.

For the fMRI study:

  • Given the limited size of the magnet bore, individuals with a body weight over two-hundred and fifty pounds will be unable to be tested within the MRI scanner.
  • Women in the latter stages of pregnancy may be excluded due to large body size and potential discomfort while in the MRI apparatus. Please note that girls who are taking part in the drug portion of the study (this includes all female subjects except the 5 healthy adult, control women) will be given 3 pregnancy during the drug study. This is to rule out pregnancy since pregnant girls should not be taking the study medications for safety reasons.
  • Standard contraindications for fMRI studies include: cardiac pacemaker, aneurysm clip, cochlear implants, shrapnel, history of metal fragments in eyes, claustrophobia
  • Participants with an IQ of less than 70 (assessed by WRAT) are likely to be excluded due to difficulties comprehending tasks and procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00176228

Contacts
Contact: Melissa S Moss, BA 312-355-1911 mmoss@psych.uic.edu
Contact: Erin M Harral, BA 312-413-1710 eharral@psych.uic.edu

Locations
United States, Illinois
NPI, University of Illinois at Chicago Recruiting
Chicago, Illinois, United States, 60612
Contact: Mani Pavuluri, MD    312-413-1722    mpavuluri@psych.uic.edu   
Contact: Erin M Harral, BA    312-413-1710    eharral@psych.uic.edu   
Principal Investigator: Mani Pavuluri, MD         
Sponsors and Collaborators
University of Illinois at Chicago
GlaxoSmithKline
Investigators
Principal Investigator: Mani Pavuluri, MD University of Illinois at Chicago
  More Information

No publications provided by University of Illinois at Chicago

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00176228     History of Changes
Other Study ID Numbers: 2003-04
Study First Received: September 13, 2005
Last Updated: April 18, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Anticonvulsants
Bipolar Disorder
Disease
Affective Disorders, Psychotic
Mental Disorders
Mood Disorders
Pathologic Processes
Lamotrigine
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sodium Channel Blockers
Therapeutic Uses
Voltage-Gated Sodium Channel Blockers

ClinicalTrials.gov processed this record on November 24, 2014